Actively Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Led by Fudan University · Updated on 2026-04-16
120
Participants Needed
1
Research Sites
300 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
CONDITIONS
Official Title
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Confirmed triple-negative invasive breast cancer by histology with specific hormone receptor and HER2 status
- Locally advanced breast cancer not suitable for radical local treatment or recurrent metastatic breast cancer
- Disease progression after at least one prior treatment for advanced or metastatic TNBC
- At least one measurable lesion per RECIST 1.1 criteria, not previously treated with radiotherapy
- Normal main organ function meeting specific blood counts and biochemical test thresholds
- No radiotherapy, molecular targeted therapy, or surgery within 3 weeks before study start and recovery from prior treatment toxicity
- ECOG performance status 0 or 1 with life expectancy of at least 3 months
- Fertile women must use medically approved contraception during treatment and for 3 months after last study drug use
- Willingness to provide informed consent, comply with study procedures, and follow-up
You will not qualify if you...
- Use of radiotherapy (except palliative), chemotherapy, or immunotherapy within 3 weeks before treatment, except bisphosphonates for bone metastasis
- Uncontrolled central nervous system metastases requiring symptomatic treatment
- History of significant or uncontrolled heart disease within the last 6 months
- Persistent grade 1 or higher adverse reactions from prior treatments, except hair loss or deemed acceptable by investigators
- Major surgery within 3 weeks before trial treatment, except minor outpatient procedures
- Pregnant or lactating women
- History of malignancy in the past 5 years, except cured basal cell carcinoma or cervical carcinoma in situ
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Actively Recruiting
Research Team
Z
Zhimin Shao, M.D.
CONTACT
Y
Yin Liu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here